RDHL vs SUPN vs PRAX vs MCK

For growth investors, RedHill Biopharma Ltd.

(RDHL) is the stronger pick with 23. 2% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Supernus Pharmaceuticals, Inc. (SUPN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, McKesson Corporation is actually cheaper at 16.

7x.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to -100. 0% for RedHill Biopharma Ltd. (RDHL). Over 10 years, the gap is even starker: MCK returned +339. 0% versus RDHL's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Praxis Precision Medicines, Inc. 's 1. 40β — meaning PRAX is approximately -8641% more volatile than MCK relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 110% for McKesson Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), RedHill Biopharma Ltd.

(RDHL) is pulling ahead at 23. 2% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 49. 2% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

McKesson Corporation (MCK) is the more profitable company, earning 1.

2% net margin versus -102. 8% for RedHill Biopharma Ltd. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 5% versus -181. 7% for RDHL. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, McKesson Corporation (MCK) trades at 16.

7x forward P/E versus 20. 8x for Supernus Pharmaceuticals, Inc. — 4. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAX: 66. 3% to $548. 80.

In this comparison, MCK (0.

4% yield) pays a dividend. RDHL, SUPN, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02), +339. 0% 10Y return). Both have compounded well over 10 years (MCK: +339. 0%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RDHL is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; MCK is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.